Maximise Lab Design with Fast Lab.
Discover the pioneering use of a platforms approach to Design for Manufacture and Assembly (P-DfMA) and how it contributed to a remarkable reduction in whole-life carbon emissions..Through Helen's expert insights, learn about the collaborative efforts and innovative strategies that make The Forge a model for future construction projects aiming for environmental excellence.Through this 'In Short' episode,.
delves into the challenges and breakthroughs in pharmaceutical manufacturing, exploring how new approaches like process intensification, automation, and continuous processing can lead to more agile, cost-effective, and environmentally friendly production methods.. Click the 'play button' above to listen in, or read our 5 Key Takeaways from this episode below.... 1.Revolution in small molecule API production:.The episode highlights the transformative research and development in small molecule Active Pharmaceutical Ingredients, emphasising the generation of new, more complex, and targeted molecules.
This revolution is pivotal for advancing the mainstay of essential medicines globally.. 2.Challenges in traditional manufacturing:.
Adrian La Porta discusses the limitations of current manufacturing practices, particularly batch chemistry, in meeting the modern demands for higher volumes, complex products, and faster production at lower costs, all while minimising environmental impact.
He points out the inefficiencies and hazards of scaling up production using traditional methods.. 3.The key lies with the big owners.
Marks calls them ‘serial owners,’ because they are large-scale, repeat asset builders.It’s when those big owners start making demands that the shifts occur.
She refers to big-budget school programmes as an example and talks about their need for operational consistency, usually over large geos.However, she cautions that after owners demand the change, it’s important they’re involved in allowing people to change the process to decrease risk and make things possible.. Jaimie Johnston points out that people often want innovation, but they want it to be tried and tested, without extra risk.